ClinicalTrials.gg
RecruitingNCT05004987Updated May 6, 2026

Aβ Dynamics in LLMD

A Phase 4 interventional study of Escitalopram Oxalate and Placebo in Alzheimer Disease and Major Depressive Disorder, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Feb 2022; still recruiting 4 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing escitalopram in Alzheimer Disease — 1 open to participants now, 2 under way, 1 of them phase 3. Escitalopram · Alzheimer Disease.

Planned enrollment
4th of 10
60 · median 55
Started
2022
the only one that year
Phase 4
5 of 10
1 open now
Registered
10th of 10
by date
Lead sponsor
2 of 10
NYU Langone Health

Among the 10 studies testing escitalopram in Alzheimer Disease, this one is the 4th largest by planned enrollment, is the only one that started in 2022, is one of 5 in phase 4, and was the 10th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

1 of the 10 studies testing escitalopram in Alzheimer Disease is open now, in 1 country.

By country, each count listing its studies:

About escitalopram

Escitalopram: first FDA approval 2002 (LEXAPRO). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing escitalopram in Alzheimer Disease, or all of them as a file.
02

Study summary

This study will examine the biological factors that may modulate the relationship between depression and the development of Alzheimer's disease (AD). Since the direction of causation between depression and the biological factors associated with AD is unknown, the only way to understand cause and associated risk is to treat the depressive symptoms and examine the effects on AD biomarkers. The study involves an FDA-approved treatment for major depressive disorder. It will compare the SSRI antidepressant escitalopram with placebo. The hypothesis is that a reduction in depressive symptoms will be associated with a normalization of CSF AD biomarkers as well as peripheral inflammatory markers. This research would contribute to fundamental knowledge about potentially modifiable risks of Alzheimer's disease (AD).

03

Conditions studied

  • Alzheimer Disease
  • Major Depressive Disorder
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female subjects, age 60+ years inclusive, at the time of signing the .
  2. Meeting Structured Clinical Interview (SCID-5-RV) for criteria for Major depressive disorder.
  3. Montgomery-Åsberg Depression Rating Scale (MADRS) ≥18.
  4. Have results of a physical examination, neurological examination, vitals, and within normal limits at screening.
  5. Cognitively unimpaired at screening visit as defined by (MMSE) >27.
  6. Clinical Dementia Rating Scale (CDR) Global of 0*.
  7. A score of 85 or greater on the RBANS delayed memory index score.
  8. Fluent in English, because some of the instruments used in this study have not been translated and validated in other languages, and are able to read at a 6th grade level or equivalent, as determined by the PI.
  9. Medically stable with no significant cerebrovascular, neurological, or systemic disease expected to interfere with the study.
  10. Adequate auditory acuity and normal-to-corrected vision.
  11. Willing to undergo brain MRI, urine drug screen and blood sampling for routine laboratory testing, lumbar puncture, APOE genotyping and plasma drug levels.
  12. Only individuals with normal or non- abnormalities on routine laboratory tests, will be included.

    • If study partner is not available, the CDR will be skipped.

Exclusion criteria

Exclusion Criteria:

  1. History of brain tumor, MRI evidence of brain damage or brain disease including significant trauma, hydrocephalus, seizures, or confluent (or more extensive) white matter hyperintensities.
  2. Mental retardation, or other serious neurological disorder (e.g. Parkinson's disease or other movement disorders).
  3. Subjects with a Fazekas scale >2.
  4. Significant history of alcoholism or drug abuse in the past 2 years. Fulfilling SCID-5-RV/ criteria for current or past diagnosis of any psychiatric disorder (e.g., schizophrenia, bipolar disorder, or any psychotic disorder) other than recurrent MDD or anxiety disorders (e.g., panic disorder, agoraphobia, etc.).
  5. A current significant risk for suicidality based on the Columbia-Suicide-Severity Rating Scale (C-SSRS).
  6. Insulin dependent diabetes.
  7. Evidence of or unstable cardiac, pulmonary, endocrine or hematological conditions.
  8. Any prosthetic devices (e.g., pacemaker or surgical clips) that constitutes a hazard for MRI imaging.
  9. Positive urine drug screen for illicit drugs.
  10. History of poor tolerance to, poor response to, or ongoing treatment with escitalopram.
  11. If taking antidepressants, currently taking fluoxetine, due to the length of time required to washout.
  12. Treatment with following medications will not be permitted. In some cases, medications will be allowed if medically prescribed and dose regimen stable. Note: Some medications (e.g., amphetamines, opiates) may appear on the routine urine drug test in the screening period but can be allowed as per protocol.

    • For subjects taking prescribed psychoactive medications and supplements (i.e., opioids, amphetamines, amphetamine-like substances, and cannabinoids), must be on a stable dose for 1 month prior to randomization.
    • Anti-Parkinsonian medications (carbidopa/levodopa, amantadine, bromocriptine, pergolide, selegiline).
    • Cholinesterase inhibitors and memantine
    • Continuous aspirin (any dosage) use which can affect function is prohibited. Exception: If participant is on low dose aspirin for prophylaxis and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before).
    • Continuous use of other medications which are also known to affect platelet function, including nonsteroidal anti-inflammatory drugs (NSAIDs), anti-histamines. Exception: If participant is taking medication continuously and is willing to temporarily discontinue prior to research blood draw (i.e., 2 days before)
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Escitalopram (ESC)

    Drug: Escitalopram Oxalate

  • Placebo comparator
    Placebo (PBO)

    Drug: Placebo

Interventions

  • DrugEscitalopramStudies of EscitalopramEscitalopram pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The daily dose of ESC/PBO will be 10 mg for the first 2 weeks, then increase to 20 mg as tolerated, with an option to reduce back to 10 mg if necessary.

    Also known as: Lexapro, ESC

  • DrugPlacebo

    Daily dose of placebo will mimic that of ESC.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. Change in Cerebrospinal Fluid (CSF) Aβ40 Biomarker Levels

    Time frame: Baseline, Week 8

  2. Change in Cerebrospinal Fluid (CSF) Aβ42 Biomarker Levels

    Time frame: Baseline, Week 8

  3. Change in Vascular Dysfunction (VD) Biomarker Levels

    Time frame: Baseline, Week 8

  4. Change in Scores on Montgomery-Asberg Depression Ration Scale (MADRS)

    MADRS consists of 10 items evaluating core symptoms of depression (e.g, apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thought, and suicidal thoughts). Each symptom is rated on a 0-6 scale (0=no abnormality, 6=severe). The total score ranges from 0 to 60; the higher the score, the more severe the symptoms.

    Time frame: Baseline, Week 8

Other outcomes

  1. Change in Plasma Aβ Biomarker Levels

    Time frame: Baseline, Week 8

  2. Change in Cerebrospinal Fluid (CSF) P-tau Biomarker Levels

    Time frame: Baseline, Week 8

  3. Change in Cerebrospinal Fluid (CSF) T-tau Biomarker Levels

    Time frame: Baseline, Week 8

07

Study locations

2 of 2 sites recruiting
  • NYU Langone Health
    New York, New York 10016, United States
    Recruiting
    • Nunzio Pomara, MD · Principal investigator
  • Nathan S. Kline Institute for Psychiatric Research
    Orangeburg, New York 10962, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared upon reasonable request.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data will have access to the data upon reasonable request. Requests should be directed to nunzio.pomara@nki.rfmh.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Dec 2026, 58 months after the start.

Of 42 phase 4 interventional studies under Alzheimer Disease, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 58 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Aug 13, 2021
StartActual
Feb 4, 2022
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05004987
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Aug 13, 2021
Start date
Feb 4, 2022
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
May 6, 2026

Study contacts

Antero Sarreal, MD
Contact
Antero.sarreal@nki.rfmh.org
845-398-6532
Chelsea Reichert Plaska, PhD
Contact
Chelsea.reichert@nki.rfmh.org
845-398-5583
Nunzio Pomara, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Escitalopram

Start the discussion